Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders-Reference-Cited by-同舟云学术

Autologous, lentivirus‐modified, T‐rapa cell “micropharmacies” for lysosomal storage disorders

Published:2022-03-17 Issue:4 Volume:14 Page:
ISSN:1757-4676
Container-title:EMBO Molecular Medicine
language:en
Short-container-title:EMBO Mol Med

Author:

Nagree Murtaza S¹²^ORCID,Felizardo Tania C³,Faber Mary L²^ORCID,Rybova Jitka²^ORCID,Rupar C Anthony⁴^ORCID,Foley S Ronan⁵,Fuller Maria⁶^ORCID,Fowler Daniel H³,Medin Jeffrey A¹²⁷^ORCID

Affiliation:

1. Department of Medical Biophysics University of Toronto Toronto ON Canada

2. Department of Pediatrics Medical College of Wisconsin Milwaukee WI USA

3. Rapa Therapeutics Rockville MD USA

4. Department of Pathology and Laboratory Medicine Western University London ON Canada

5. Juravinski Hospital and Cancer Centre McMaster University Hamilton ON Canada

6. Genetics and Molecular Pathology SA Pathology at Women's and Children's Hospital North Adelaide SA Australia

7. Department of Biochemistry Medical College of Wisconsin Milwaukee WI USA

Funder

Midwest Athletes Against Childhood Cancer

Publisher

EMBO

Subject

Molecular Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.15252/emmm.202114297

Reference58 articles.

1. Clinical Manual of Blood and Bone Marrow Transplantation

2. High Overexpression of the Human α-Galactosidase A Gene Driven by Its Promoter in Transgenic Mice: Implications for the Treatment of Fabry Disease

3. A simple fluorogenic method for determination of acid ceramidase activity and diagnosis of Farber disease

4. The impact of the immune system on the safety and efficiency of enzyme replacement therapy in lysosomal storage disorders

5. Pharmacokinetics of Natural and Engineered Secreted Factors Delivered by Mesenchymal Stromal Cells

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Fabry nephropathy: a treatable cause of chronic kidney disease;Rare Disease and Orphan Drugs Journal;2024-07-11

2. Engineering Memory T Cells as a platform for Long-Term Enzyme Replacement Therapy in Lysosomal Storage Disorders;2024-04-28

3. Generation and characterization of an immunodeficient mouse model of mucopolysaccharidosis type II;Molecular Genetics and Metabolism;2023-04

4. Cell and gene therapy for kidney disease;Nature Reviews Nephrology;2023-03-27

5. Ex vivo gene therapy for lysosomal storage disorders: future perspectives;Expert Opinion on Biological Therapy;2023-03-20